Bank of Montreal Can Has $229.48 Million Stock Position in McKesson Corporation $MCK

Bank of Montreal Can cut its position in McKesson Corporation (NYSE:MCK) by 24.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 297,051 shares of the company’s stock after selling 94,763 shares during the quarter. Bank of Montreal Can owned approximately 0.24% of McKesson worth $229,484,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of MCK. Norges Bank acquired a new position in shares of McKesson during the second quarter worth approximately $1,346,661,000. Alliancebernstein L.P. grew its stake in shares of McKesson by 150.4% in the second quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock worth $1,661,956,000 after acquiring an additional 1,362,386 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of McKesson by 56.4% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock worth $906,109,000 after acquiring an additional 446,060 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in McKesson by 45.6% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock worth $610,977,000 after acquiring an additional 261,296 shares during the period. Finally, Vanguard Group Inc. increased its position in McKesson by 2.0% during the second quarter. Vanguard Group Inc. now owns 12,072,090 shares of the company’s stock worth $8,846,186,000 after acquiring an additional 232,286 shares during the period. Institutional investors own 85.07% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on MCK shares. Raymond James Financial set a $970.00 price target on shares of McKesson in a report on Thursday, March 5th. Weiss Ratings lowered shares of McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research report on Thursday, February 5th. Evercore reiterated an “outperform” rating on shares of McKesson in a research note on Thursday, March 5th. Wells Fargo & Company lifted their target price on McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 5th. Finally, Morgan Stanley restated an “overweight” rating and set a $966.00 price target on shares of McKesson in a research note on Thursday, January 29th. Thirteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, McKesson has an average rating of “Moderate Buy” and an average target price of $960.93.

Insider Activity

In other McKesson news, EVP Leann B. Smith sold 190 shares of McKesson stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total transaction of $179,550.00. Following the completion of the transaction, the executive vice president directly owned 2,989 shares of the company’s stock, valued at approximately $2,824,605. This trade represents a 5.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Maria Martinez sold 349 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $939.87, for a total transaction of $328,014.63. Following the sale, the director owned 301 shares of the company’s stock, valued at $282,900.87. This trade represents a 53.69% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 3,868 shares of company stock valued at $3,743,820. 0.08% of the stock is owned by company insiders.

McKesson Stock Performance

Shares of McKesson stock opened at $928.60 on Wednesday. The firm has a market cap of $113.74 billion, a P/E ratio of 26.71, a price-to-earnings-growth ratio of 1.52 and a beta of 0.38. The firm’s 50-day simple moving average is $886.79 and its 200-day simple moving average is $820.88. McKesson Corporation has a twelve month low of $635.00 and a twelve month high of $999.00.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The firm had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. During the same quarter last year, the company earned $8.03 earnings per share. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, equities analysts forecast that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, March 2nd. McKesson’s dividend payout ratio is 9.43%.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.